Bumetanide Injection
NDC Package 83301-0080-2
Package Information
Bumetanide injection is bumetanide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This formulation utilizes a injection delivery system. Marketed by Mullan Pharmaceutical Inc., this product is identified by NDC 83301-0080 and is authorized under FDA application ANDA219116.
Identification & Billing
- RxCUI: 1727569 - bumetanide 1 MG in 4 ML Injection
- RxCUI: 1727569 - 4 ML bumetanide 0.25 MG/ML Injection
- RxCUI: 1727569 - bumetanide 1 MG per 4 ML Injection
- RxCUI: 282486 - bumetanide 0.25 MG/ML Injectable Solution
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 83301 - Mullan Pharmaceutical Inc.
- 83301-0080 - Bumetanide
- 83301-0080-2 - 10 VIAL, SINGLE-DOSE in 1 CARTON / 4 mL in 1 VIAL, SINGLE-DOSE (83301-0080-1)
- 83301-0080 - Bumetanide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83301-0080-2 identifies a specific commercial package of 10 vial, single-dose in 1 carton / 4 ml in 1 vial, single-dose (83301-0080-1) of Bumetanide, a human prescription drug labeled by Mullan Pharmaceutical Inc.. This injection is formulated for intramuscular; intravenous use and contains bumetanide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mullan Pharmaceutical Inc. on August 12, 2025. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Bumetanide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. Bumetanide is a "water pill" (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.
How is this Mullan Pharmaceutical Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83301008002. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.